» Articles » PMID: 35268374

Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Mar 10
PMID 35268374
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) gene and presently, 360 CFTR-causing mutations have been identified. Since the discovery of the CFTR gene, the expectation of developing treatments that can substantially increase the quality of life or even cure cystic fibrosis patients is growing. Yet, it is still uncertain today which developing treatments will be successful against cystic fibrosis. This study addresses this gap by assessing the opinions of over 524 cystic fibrosis researchers who participated in a global web-based survey. For most respondents, CFTR modulator therapies are the most likely to succeed in treating cystic fibrosis in the next 15 years, especially through the use of CFTR modulator combinations. Most respondents also believe that fixing or replacing the CFTR gene will lead to a cure for cystic fibrosis within 15 years, with CRISPR-Cas9 being the most likely genetic tool for this purpose.

Citing Articles

Advances for pediatricians in 2022: allergy, anesthesiology, cardiology, dermatology, endocrinology, gastroenterology, genetics, global health, infectious diseases, metabolism, neonatology, neurology, oncology, pulmonology.

Caffarelli C, Santamaria F, Piro E, Basilicata S, DAntonio L, Tchana B Ital J Pediatr. 2023; 49(1):115.

PMID: 37679850 PMC: 10485969. DOI: 10.1186/s13052-023-01522-8.


Advances in Cystic Fibrosis Research in Qatar: A Commentary.

Hammoudeh S, Janahi I J Pers Med. 2023; 13(3).

PMID: 36983631 PMC: 10055988. DOI: 10.3390/jpm13030448.


Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index.

Terlizzi V, Castellani C, Taccetti G, Ferrari B Ital J Pediatr. 2022; 48(1):141.

PMID: 35927765 PMC: 9351191. DOI: 10.1186/s13052-022-01331-5.

References
1.
Martiniano S, Sagel S, Zemanick E . Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr. 2016; 28(3):312-7. PMC: 4946574. DOI: 10.1097/MOP.0000000000000351. View

2.
Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V . The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Expert Opin Drug Discov. 2020; 15(8):873-891. DOI: 10.1080/17460441.2020.1750592. View

3.
Marquez Loza L, Yuen E, McCray Jr P . Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. Genes (Basel). 2019; 10(3). PMC: 6471883. DOI: 10.3390/genes10030218. View

4.
Ong V, Mei V, Cao L, Lee K, Chung E . Nanomedicine for Cystic Fibrosis. SLAS Technol. 2019; 24(2):169-180. DOI: 10.1177/2472630318824334. View

5.
Cao H, Ouyang H, Laselva O, Bartlett C, Zhou Z, Duan C . A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations. Eur Respir J. 2020; 56(5). DOI: 10.1183/13993003.00205-2020. View